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Abstract
De novo  neoplasms account for almost 30% of deaths 
10 years after liver transplantation and are the most 
common cause of mortality in patients surviving at 
least 1 year after transplant. The risk of malignancy is 
two to four times higher in transplant recipients than 
in an age- and sex-matched population, and cancer 
is expected to surpass cardiovascular complications 
as the primary cause of death in transplanted pa-
tients within the next 2 decades. Since exposure to 
immunosuppression is associated with an increased 
frequency of developing neoplasm, long-term immuno-
suppression should be therefore minimized. Promising 
results in the prevention of hepatocellular carcinoma 
(HCC) recurrence have been reported with the use of 
mTOR inhibitors including everolimus and sirolimus 
and the ongoing open-label prospective randomized 
controlled SILVER. Study will provide more information 
on whether sirolimus-containing vs  mTOR-inhibitor-
free immunosuppression is more efficacious in reducing 
HCC recurrence.
Key words: Liver transplantation; De novo  neoplasms; 
Immunosuppression; mTOR inhibitors; Hepatocellular 
carcinoma
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Core tip: With the notable increase in life expectancy 
after liver transplantation, together with the lengthy 
exposure to immunosuppression, transplant recipients 
are at risk of developing neoplastic disease, which 
accounts for almost 30% of deaths 10 years after liver 
transplantation. The risk of malignancy is two to four 
times higher in transplant recipients than in an age- 
a higher toll on survival[8]. Mortality after diagnosis of 
de novo malignant neoplasms is particularly elevated, 
with reported rates as high as 55% and a median 
survival of 54 mo after diagnosis[7]. Overall, estimated 
survival rates for all types of de novo malignancies 
are reportedly 70%, 56%, 48%, and 39% after 1, 
3, 5, and 10 years, respectively. For certain types of 
cancer, mortality is particularly high, reaching 100% 
for lung cancer, 62.5% for esophageal and gastric 
cancers, 57% for head and neck cancer, 50% for post-
transplant lymphoproliferative disorder (PTLD), and 
50% for Kaposi Sarcoma (KS)[7]. 
Types of de novo neoplasms
De novo malignancies are neoplasms that develop 
after transplantation, including solid tumors such 
as pancreatic cancer, lung cancer, colorectal cancer, 
gastric cancer, esophageal cancer, renal cell carcinoma, 
bladder cancer, thyroid cancer, oral cancer, brain 
tumors and laryngeal cancer, as well as non-solid 
tumors, primarily PTLD/non-Hodgkin Lymphoma (NHL) 
and leukemia. According to a large German study 
analyzing the frequency and distribution of de novo 
neoplasms after LT[9], 1 de novo malignancy is to be 
expected approximately every 120 person-years after 
LT (120 de novo malignancies/14490 person-years). 
It was also shown that cancer incidence rates for LT 
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Table 1  Estimated standardized incidence ratios for de novo  
malignancies after liver transplantation (data according 
to[7,9,15,46-48,61,72,174-182])
Cancer site/type Estimated 
incidence (%)
SIR
All cancers 5-6 1.94-3
Kaposi’s sarcoma 0.14-2.8   > 100
Skin (non melanoma)   0.9-3.2 > 30
PTLD   0.9-2.6 6-20
Gastrointestinal and 
oropharyngeal sites
Lip/oropharyngeal/head and 
neck cancers
  0.1-2.0 5-14
Esophagus1    0.5-1.19 12-18.7
Colorectal overall    0.0-0.65 1.41
Colorectal in IBD/PSC   0.7-7.9 3-5
Stomach 0.25 3
Vulva 0.25 8-23.8
Lung   0.6-1.2 2-8
Renal 0.35 2-2.65
Thyroid 0.20 4.60
Prostate 0.25-0.6 1 (risk not increased)
Breast 0.40 1 (risk not increased)
Colorectal in non-IBD/PSC 0.30 1 (risk not increased)
1Although there are no population-based SIR estimates showing an 
increased risk of esophageal cancer after LT, an Italian study reported an 
SIR of 23.4 on the basis of cases ascertained by medical record reviews[178]. 
This association may be related to prior alcohol exposure; 2 of 3 patients 
diagnosed with esophageal cancer in a US cohort underwent LT for ALD[1]. 
IBD: Inflammatory bowel disease; PSC: Primary sclerosing cholangitis; 
PTLD: Posttransplant lymphoproliferative disease; SIR: Standardized 
incidence ratio.
and sex-matched population, and cancer is expected 
to surpass cardiovascular complications as the primary 
cause of death in transplanted patients within the next 
2 decades, making this an important topic for clinicians 
to consider.
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InTRoDUCTIon
With excellent long-term survival rates, the causes 
of morbidity and mortality of liver transplant (LT) 
recipients are primarily cardiovascular diseases, renal 
insufficiency, and de novo neoplasm, the latter of 
which account for almost 30% of deaths at 10 years 
post transplantation. Apart from hepatic causes, 
neoplasm has been reported as the most common 
cause of death in patients surviving at least 1 year 
after LT, and is responsible for approximately 40% of 
deaths[1,2]. Overall, it is estimated that in LT recipients 
the incidence of neoplasms is between 3.1% and 
14.4%, and the cancer-related mortality rate is 
between 0.6% and 8.0%[3,4]. 
Although the risk of some neoplasms including 
breast cancer (1.9 times lower) and genitourinary 
cancer (1.5 times lower) in women seem to be reduced 
compared to those of the general population[5], in 
general terms, the status of transplant recipient is 
associated with an increased risk of developing de 
novo neoplasm. As shown in a study analyzing 1000 
consecutive LT recipients in Pittsburgh and comparing 
this population’s incidence of neoplasms compared to 
the general population, the former have a significantly 
elevated risk for developing neoplasm, which is 7.6 
times higher for oropharyngeal cancer and 1.7 times 
higher for respiratory malignancies (Table 1).
Since a more prolonged exposure to immuno-
suppression is associated with an increased frequency 
of developing neoplasms, the cumulative risk of 
developing de novo malignancy rises from 20% at 
10 years to 55% at 15 years after transplant[6]. In an 
Italian study analyzing 313 LT recipients who survived 
more than 12 mo after transplant, during a total follow-
up time of 1753 person-years, de novo malignancies 
were diagnosed in 40 (12.8%) subjects, with a median 
time from transplantation to diagnosis of 54 mo (range, 
2-159 mo)[7]. Other studies have reported a slightly 
lower mean interval between LT and diagnosis of non-
lymphoid malignancies (36.2 mo, range, 5.8-74.1)[5]. 
Not only are malignant neoplasms more frequent 
in transplant recipients, but they also have a more 
aggressive behavior, present at an earlier age 
compared to the non-transplant population, and take 
recipients are almost twice as high as those for an 
age- and sex-matched general population. To quantify 
the risk that the status of transplant recipient conveys, 
cancer site-specific incidence rates in the transplant 
population are compared against the general popu-
lation, with standardized incidence ratios (SIRs). 
Estimated SIRs for each malignancy, as well as the 
reported incidence are shown in Table 1. PTLD is the 
most frequent de novo malignancy after LT, accounting 
for approximately 20% of cases[7]. Other common 
types of de novo malignant tumors include KS (17%), 
head and neck cancer (17%), esophageal tumors 
(12%), lung cancer (10%), gastric adenocarcinoma 
(7%), melanoma (5%), colorectal cancer (5%), 
cervical cancer (5%), and breast cancer (2%), as 
shown in a study from Northern Italy[7]. 
Skin cancer
In a series of LT recipients with nonlymphoid de novo 
malignancies, skin cancer was reportedly the most 
common type of malignancy (22/57 patients with de 
novo cancer, representing 33.3%), including squamous 
cell carcinomas in 50%, basal cell carcinomas in 
40.9%, and melanomas in 9.1%. Neoplasms were 
most frequent on the skin of the head, face, and neck 
(in 14 subjects), but there were also several cases of 
multiple site involvement, and the mean time to onset 
was 36.4 mo (range, 8.2-75.1 mo)[5]. Another study 
demonstrated that the prevalence of pre-malignant 
and neoplastic cutaneous lesions increased with time, 
with a frequency of premalignant lesions of 5% at 
2-3 years, 12% at 3-5 years, 28% beyond 5 years, 
and frequency of malignant lesions of 0% at 2-3 
years, 9% at 3-5 years, and 12% beyond 5 years of 
follow-up after transplantation. Furthermore, in that 
same study, the cumulative incidence of cutaneous 
lesions was significantly higher in patients treated with 
cyclosporine compared to recipients on tacrolimus[10]. 
One-year survival after diagnosis of skin cancer in LT 
recipients is reportedly 90.9%[5]. Several factors have 
been identified as being considered high risk for deve­
loping skin cancer, including increased age, increased 
intensity and longer duration of immunosuppressive 
therapy, infection with human papillomavirus, history 
of increased ultraviolet exposure, easily burned skin, 
history of actinic keratosis, CD4 lymphocytopenia, 
and blue or hazel eyes[11,12]. Primary sclerosing cho-
langitis[13] as well as alcohol-related liver disease as 
indications for LT are associated with a higher risk of 
skin malignancies compared to other etiologies of liver 
disease[14,15]. Other risk factors for the development of 
skin malignancy after LT include male sex, age over 
55 years, Caucasian background, and monoclonal 
antibody induction therapy[11], while the use of poly-
clonal or interleukin (IL)-2 receptor antibody induction 
therapy, treatment for rejection, and non-cholestatic 
etiologies of liver disease as indications for LT, seem 
not to be associated with an increased risk. 
PTLDs
PTLD encompasses a heterogeneous group of diseases 
characterized by excessive proliferation of lymphoid 
cells and it commonly results from de novo infection 
or reactivation of latent Epstein-Barr virus (EBV)[16,17], 
especially in the case of EBV seronegative recipients 
of organs from EBV seropositive donors. LT carries an 
intermediate risk of PTLD, in contrast with intestinal 
transplantation, which has the highest rates[18,19]. 
An increased intensity of immunosuppression[5,20-23] 
and the use of certain types of immunosuppressive 
agents, in particular T-cell depleting antibodies such 
as Muromonab-CD3 (OKT3) or anti-thymocyte glo-
bulin (ATG), cyclosporine, and belatacept (in renal 
transplant recipients) constitute additional risk factors 
for PTLD development[24-26]. In an Italian study, 15 
cases of PTLD were described in 1011 solid organ 
transplant recipients; in 13/15 patients, induction 
immunosuppressive therapy with OKT3 was used, 
and EBV was detected in 10 of 13 patients in whom 
neoplastic tissue was available for analysis. Moreover, 
in 2 of the 3 patients who were negative for EBV, 
hepatitis C virus (HCV) was present, and positivity 
for HCV was significantly more frequent in patients 
who developed PTLD compared to those who did not, 
suggesting a possible role of HCV in the development 
of PTLD[19]. Other studies have also shown a correlation 
between the presence of HCV and the development of 
PTLD[27-29].
In the pediatric population, PTLD is the most 
common tumor in solid organ recipients, with an 
overall incidence rate of 5% to 15% in different series 
or 298/100000 posttransplantation years of follow-
up[30,31]. Reported mortality is unfortunately very high, 
of up to 60%, especially in infants who develop PTLD 
as a result of primary EBV transmission from EBV-
positive allograft transplant[32-35].
The most important risk factors for PTLD develop-
ment in the pediatric population include high levels 
of immunosuppression (especially associated with 
tacrolimus-based regimens[36]), young age, time 
from transplant (related to longer exposure time 
to immunosuppression), EBV seronegativity before 
transplant, and primary EBV transmission. Fukushima 
and collaborators, in a recently published study on 32 
infants younger than 2 years who had undergone living-
donor liver transplantation and were on tacrolimus-
based immunosuppression, found that deteriorated 
tacrolimus metabolism (with elevated plasmatic levels) 
accompanied by an increase in Epstein-Barr viral load 
was more frequently associated with PTLD[36]. In a 
recently published paper by the Studies of Pediatric 
Transplantation Research Group[37] analyzing a large 
multicenter cohort of pediatric patients who underwent 
LT, transplants performed in the era 1995-2001 (vs 
those performed between 2002 and 2007), recipient 
EBV status, and frequent rejection episodes were 
associated with symptomatic EBV infection and 
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LT recipients is increased compared to the general 
population, and reportedly accounted for 15.7% of 
nonlymphoid neoplasms in a series of LT recipients, in 
whom it was diagnosed, on average, 48.5 mo (range, 
11.2 to 64.3 mo) after LT, and a one-year survival 
of 37.5%[5]. In large case series of LT recipients, the 
mean time to diagnosis ranges from 42 to 50 mo[5,46-48]. 
Akin to the association between smoking observed in 
the general population, this carcinogen is correlated 
with an increased risk of lung cancer in transplant 
recipients[5,46]. Although probably representing an 
epidemiological association, as smokers are also 
frequently heavy drinkers, a study showed that 
patients with alcohol-related cirrhosis as an indication 
for LT had higher rates of lung cancer than those who 
underwent LT for other indications[49]. 
Head and neck cancers: Head and neck neoplasms 
are more frequent in the LT population than in the 
general population, and mean time to diagnosis is 
reportedly between 34.3 mo and 61.2 mo[5,15,47,50,51]. 
Oropharyngeal cancer is 25.5 times more frequent in 
patients transplanted for alcohol-related cirrhosis vs 
those transplanted for other indications[52]. Moreover, 
upper aerodigestive squamous carcinomas are more 
frequent in patients with alcohol-related cirrhosis as 
the main indication for LT[53]. Moreover, another study 
showed that whereas the incidence of oropharyngeal 
cancer was 16.7% in patients who underwent LT for 
alcohol-related liver disease, none of the patients 
who underwent LT for indications other than alcohol-
related cirrhosis developed oropharyngeal malignant 
neoplasms (P = 0.001)[50]. Notably, there was not one 
case of oropharyngeal cancer in a small, single-center 
study involving patients without a history of smoking or 
alcohol use[54]. Likewise, tongue cancer and laryngeal 
cancer have been reported in smokers[5,46], and the 
carcinogenic effects of tobacco observed in the general 
population also applies for transplant recipients. It is 
difficult to establish the weight of alcohol compared to 
tobacco use as contributing risk factors for head and 
neck neoplasms, as alcohol is known to potentiate 
the carcinogenic effects of smoking[55], and also since 
patients who are heavy smokers also tend to be heavy 
drinkers[56]. 
Esophageal and gastric cancer: Although their 
incidence is increased with respect to the general 
population[57], gastric and esophageal cancers are 
reported infrequently in most series of LT recipients[58]. 
As well as for several other types of cancer, notably 
those of the oropharynx/larynx, alcohol is a well-
established risk factor for esophageal malignant 
neoplasms[59], and this neoplasm occurs at a higher 
rate after LT in patients with alcohol-related liver 
disease[15,27,60]. In an Italian study on 313 LT recipients 
followed during a 15-year period, of 40 patients with 
de novo malignancy, esophageal cancer was diagnosed 
PTLD. The subgroup at a highest risk is constituted 
by younger infants with multiple rejection episodes. 
Importantly, the incidence of both symptomatic 
EBV infection and PTLD are seemingly decreasing in 
pediatric LT recipients, concomitantly with a reduction in 
immunosuppression[37]. 
In a recent study, Khedmat and Taheri[38] reviewed 
250 cases of PTLD after liver transplantation published 
in the literature, of whom 212 were pediatric cases (18 
years of age or less). PTLD was diagnosed at a mean 
age of 9.9 years and the mean ± SD interval between 
LT and diagnosis of PTLD was 28.7 mo (35.1 mo). 
Organs/areas involved included: orbit, skin, stomach, 
genitalia, central nervous system, spleen, kidneys, 
respiratory system, liver, bone marrow, small intestine, 
and colon; in comparison with their adult counterparts, 
histopathological features of PTLD were significantly of 
more benign types. 
Analogous to management strategies in adults, 
a sequential approach is employed, starting with 
reduction or complete withdrawal of immunosup-
pression, initiation of inferferon-alpha, various 
chemotherapic regimens, surgery, and radiotherapy, 
escalating strategies if the previous alternative proves 
inefficacious[39]. Moreover, long-term withdrawal of 
immunosuppression has been shown to be feasible 
without graft rejection[40]. The use of the anti-B-
cell monoclonal antibody rituximab has brought 
about improved results, and more recently, Gupta 
and collaborators reported on satisfactory outcomes 
employing a dual combination of rituximab and reduced 
dose chemotherapy, with two-year failure-free survival 
of 57% in liver transplant recipients[39]. 
Kaposi’s sarcoma
KS is a multifocal angioproliferative mucocutaneous 
neoplasm driven by HHV-8 infection and represents 
approximately 4% of all post-transplant tumors. The 
risk of developing this neoplasm is increased 500-fold 
in solid organ transplant recipients compared with 
the general population[41,42]. In a large study on 2705 
recipients of solid organs, amongst whom 159 LT 
recipients, KS was diagnosed in 1.44% of all transplant 
recipients, including 12.8% of LT recipients[43]. 
Contrary to most other neoplasms, the incidence of 
KS seems to decrease significantly with time after 
solid organ transplantation[44]. In the presence of 
infection with HHV-8, the most important risk factor 
for the development of this neoplasm is the intensity 
of immunosuppression, and its therapy is based on 
immunosuppression tapering, as well as the use 
of chemotherapeutic agents. Moreover, evidence is 
mounting on the usefulness of mTOR inhibitors in 
treating this tumor while at the same time providing 
effective immunosuppression[45]. 
Solid tumors
Lung cancer: The incidence of lung cancer among 
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in 12%, with a mortality (combined for esophageal 
and gastric cancer of 62.5%) being second only to that 
of lung cancer[7]. A German study analyzing 1,926 LT 
recipients found that 9 patients (0.5%) developed a 
de novo esophageal cancer and 1 patient developed 
cancer of the cardia (0.05%), diagnosed on average 
51 mo after LT. The histological type of tumor was 
squamous cell carcinoma in 7/10 and adenocarcinoma 
in 3/10. Of note, 9/10 patients had undergone LT due 
to alcohol-related cirrhosis[61]. A predisposing lesion, 
Barrett’s esophagus, has been demonstrated to rapidly 
evolve into adenocarcinoma after LT, which is why 
surveillance endoscopy with aggressive endoscopic 
treatment of Barrett’s mucosa is paramount in these 
patients to prevent death from cancer[62-66]. In a Korean 
study of 6491 patients who underwent solid organ 
transplantation, 30 patients (0.46%) with 31 lesions 
were diagnosed with gastric cancer[67]. In another 
series, 36 cases of gastric cancer were identified 
among 7000 transplant-related malignant neoplasms, 
and 3 of the 34 were observed in LT recipients[68]. 
Moreover, another study reported 3 cases of gastric 
cancer amongst 329 cases of malignant neoplasms in 
LT recipients[69]. 
Genitourinary cancer: Although the incidence of 
prostate cancer does not seem to be increased in LT 
recipients, all other genitourinary cancers (including 
bladder and renal cancer) seem to be higher than 
that of the general population[5,15,27,46,47]. Mean time to 
diagnosis of non-prostate genitourinary cancer ranges 
from 20 to 55.3 mo, while in cases of prostate cancer 
the diagnosis is often performed between 5.8 and 18.4 
mo after LT[5,15,47,48]. In LT recipients, prostate cancer is 
more often diagnosed at earlier stages and has a good 
prognosis, whereas renal and bladder cancers have a 
poor prognosis[5]. 
Gynecological cancer: Although it seems that 
breast cancer is no more frequent in LT compared to 
the general population[3], non-breast gynecological 
cancers (cervical and ovarian) are more frequent in LT 
recipients than in the general population[15,46,47]. It has 
been hypothesized that rigorous screening before LT 
has contributed to a tendency, albeit not statistically 
significant, for a lower incidence of breast cancer in LT 
recipients[5]. However, other studies have documented 
that breast cancer incidence is in fact elevated in the 
transplant population, with the advantage, however, 
that early detection is more common, and this has also 
resulted in decreased mortality compared to that of 
the general population upon similar diagnoses[46]. 
Colorectal cancer: The incidence of colorectal cancer 
seems to be higher in the LT recipient population vs 
the general population[46,47], although most of this 
difference in incidence, if not all, can be accounted for 
by the increased risk of colorectal cancer associated 
with LT for primary sclerosing cholangitis, probably 
due to the association with ulcerative colitis[70-72]. More 
frequently diagnosed between 16 and 50 mo after 
transplant, colorectal cancer in transplant recipients 
tends to be detected at an earlier age and has been 
associated with a worse prognosis compared to the 
general population[73,74]. 
De novo hepatocellular carcinoma: A search 
performed by Trevisani et al[75] identified 14 cases 
of de novo hepatocellular carcinoma (HCC) which 
have been reported in the literature. Although until 
now a relatively rare occurrence, truly de novo 
HCC, that is, neoplasms arising from the liver graft 
and not recurrences of recipient HCC, might be 
seen more often in the future, due to the increased 
use of extended criteria grafts, especially those 
from older donors, donors carrying HCV or HBV 
infection, or alcoholic liver disease[76,77]. One of the 
principal risk factors for de novo HCC is recurrence 
of liver disease in the allograft, and especially the 
development of cirrhosis[75], and reported cases have 
been diagnosed on average 2 years after LT. As for 
non-transplant recipients, post transplant exposure 
to hepatocarcinogens like aflatoxin B1, nitrosamine, 
aromatic amines, vinyl chloride, azo-dyes, pesticides, 
arsenic, organic solvents, and cigarette smoking, can 
theoretically trigger the development of HCC, although 
no case has yet been reported in association with any 
of these factors. Immunosuppression regimens used 
in the 14 reported cases include OKT3, azathioprine, 
cyclosporine, corticosteroids, mycophenolate mofetil, 
basiliximab, and tacrolimus[78-82]. 
Prognosis seems dismal according to reported cases, 
despite tapering of immunosuppression, transarterial 
chemoembolization, radiofrequency ablation, hepatic 
resection, or retransplantation. Strategies for pre-
venting this neoplasm include avoidance of recurrent 
graft damage as well as a judicious immunosuppression 
after LT[75]. While HCC recurrence is considered a 
contraindication for retransplantation, this therapeutic 
option could be contemplated in the setting of de novo 
HCC and has been reported in a case with development 
of this de novo malignancy 14 years after primary 
LT[82]. 
RIsk faCToRs foR The DevelopmenT 
of de novo malIgnanCIes
In a study analyzing risk factors for the development 
of solid neoplasms after LT, multivariate analyisis 
demonstrated that primary sclerosing cholangitis (HR 
= 2.62, 95%CI: 1.50-4.56), alcohol-related cirrhosis 
(HR = 2.14, 95%CI: 1.22-3.73), smoking (HR = 1.72, 
95%CI: 1.06-2.79), and increasing age in decades 
(HR = 1.33, 95%CI: 1.05­1.66) were all significantly 
associated with de novo neoplasms[1]. A summary of 
the most important risk factors is provided in Table 2. 
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DonoR-TRansmITTeD malIgnanCIes
The role of immunosuppression in reactivating dormant 
neoplasms is supported by the fact that transplant 
recipients who have received organs from donors with 
previously cured neoplasms may develop the donor’
s malignancy[83,84]. Reportedly, 0.5% to 3% of donors 
have a history of malignancy, and transmission from 
these donors to the recipients has been demonstrated 
in 0.02%-6% of cases[85-89], the risk being higher 
in LT recipients as compared to recipients of other 
organs[90,91]. According to the time elapsed from clinical 
remission of the neoplasm in the donor to the moment 
of donation, tumor site, and risk of transmission, 
recommendations for specific tumor types have 
been issued by the Malignancy Subcommittee of the 
Disease Transmission Advisory Committee of the Organ 
Procurement and Transplantation Network/United 
Network for Organ Sharing (OPTN/UNOS). Organ 
shortage, a low risk of transmission of malignancy to 
the recipient, and the need for a life-saving transplant 
in cases of urgent LT may drive the decision of using 
organs from extended criteria donors, including donors 
with a neoplasm. It is important, however, to quantify 
the risk, based on the type of neoplasm. Thus, an organ 
from a donor with basal cell carcinoma is considered 
to be associated with a minimal risk (< 0.01%) of 
transmission and may be used as a graft, whereas at 
the other end of the spectrum, the history or presence 
of melanoma, lung cancer, or active breast cancer > 
stage 0 are considered at high risk of transmission 
(> 10%) and their use is discouraged[92]. Allegedly, 
organs from donors with central nervous system 
malignancies may be safely transplanted; in a study 
analyzing 62 recipients of organs from donors with a 
history of or active central nervous system neoplasm, 
8 transmissions were identified, occurring 2-15 mo 
after transplant, with seven patients dying as the 
result of metastatic disease. The presence of one or 
more risk factors, identified as: high-grade tumors, 
ventriculoperitoneal or ventriculoatrial shungs, prior 
craniotomy and systemic chemiotherapy, entailed a risk 
of 53% of tumor transmission, whereas the rate was 
significantly lower (7%, P < 0.01) if no risk factor was 
present[93]. However, a more recent and larger study 
performed in the United Kingdom concluded that organs 
from donors who died as a consequence of primary 
intracranial malignancy, including those with high-grade 
tumors, should be considered for transplantation due 
to the small risk of tumor transmission. Identification 
of 448 recipients of 495 organs from 177 donors with 
primary intracranial malignancy, including 33 with 
high-grade malignancy (9 medulloblastomas and 24 
grade Ⅳ gliomas amongst 179 donors) demonstrated 
not one single case of tumor transmission[94]. As in all 
medical interventions, a risk-benefit evaluation must 
be performed, the patient should be informed of the 
possibility of receiving one such organ, and this must 
be weighed against the risk of dying on the waiting list, 
which is much higher. 
The recommendations for screening in the donor 
so as to reduce the risk of undiagnosed neoplasm 
and subsequent transmission to the recipient include 
execution of complete medical history specifically 
inquiring on previous diagnosis of malignancy, 
radiological imaging, complete physical examination 
to rule out possible skin cancer, laboratory analysis for 
the detection of tumor markers, pathology examination 
of extracted organs, and in cases of unexplained 
intracranial hemorrhage and in women with menstrual 
disorders, underlying neoplasms must be excluded[95,96]. 
ImmUnosUppRessIon
Immunosuppression plays a fundamental role in the 
development of neoplasms, acting through several 
different mechanisms including decreased immune 
surveillance, increased susceptibility to infections, 
induction of insulin resistance, and a direct carcinogenic 
effect which has been described in the case of some 
immunosuppressive agents. The association between 
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Table 2  Risk factors for the development of de novo  ma-
lignancies according to tumor location/type (data according 
to[5,14-17,20-22,25,26,46,48,50,53,54,61,62,64,75,130,181,183,184])
Tumor location/type Risk factor
Skin Age > 40 yr
Male gender
Skin type
Sun exposure
Smoking
Alcoholic cirrhosis
Primary sclerosing cholangitis as indication 
for LT
Cyclosporine-based immunosuppression
KS Increased intensity of immunosuppression
Infection with HHV-8
PTLD Age > 50 yr
Infection with EBV (especially seronegative 
recipients of organs from EBV seropositive 
donors)
Increased intensity of immunosuppression
OKT3 or anti-thymocyte globulin
Cyclosporine-based immunosuppression
Hepatitis C virus
Lung cancer Cigarette smoking
LT for alcohol-related liver disease
Head and neck cancers Cigarette smoking
LT for alcohol-related liver disease
Esophageal and gastric 
cancers
LT for alcohol-related liver disease
Barrett’s Esophagus
Colorectal cancer Primary sclerosing cholangitis
Inflammatory bowel disease
De novo HCC Recurrence of liver disease in the allograft
Gynecologic cancers Insufficient evidence
Genitourinary cancers Insufficient evidence
EBV: Epstein-Barr virus; HCC: Hepatocellular carcinoma; HHV-8: Human 
herpesvirus 8; KS: Kaposi’s sarcoma; LT: Liver transplantation; PTLD: 
Post-transplant lymphoproliferative disorder.
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alterations in the immune system and the development 
of neoplasms is also reflected in the elevated incidence 
of cancer in most medical conditions associated with 
immunosuppression[97,98] and the fact that the length of 
exposure and intensity of immunosuppression correlate 
with the incidence of malignant neoplasms[99,100]. 
Whereas in immunocompetent subjects there is 
continuous ongoing surveillance that acts as tumor 
suppressor, keeping in check possible accumulated cell 
damage resulting in neoplasms, immunosuppression in 
organ transplant recipients results in a lower threshold 
for immunosurveillance, allowing neoplastic cells to 
proliferate. 
Moreover, chronic immunosuppression renders 
transplant recipients more vulnerable to viral in-
fections, some of which have oncogenic potential. 
Although not all neoplasms are the result of viral 
triggers, the ones that are tend to be those that show 
the greatest rise in frequency amongst transplant 
recipients including B-cell lymphoma and PTLD (EBV), 
squamous cell skin carcinoma (HPV), Kaposi’s sarcoma 
(HHV8), anogenital cancers (HPV), Merkel skin cancer 
(polyomavirus), and HCC (HBV, HCV)[97]. The viral 
oncogenic potential may be enhanced by the action 
of some immunosuppressants. Calcineurin inhibitors 
in particular, can favor the expression of EBV growth 
and virus-inducing factors including IL-1, IL-6, and 
transforming growth factor (TGF-β), can promote EBV 
replication, and can augment immunoresistance by 
favoring the expression of anti-apoptotic genes[101]. 
Aside from these indirect effects, several immuno-
suppressive drugs seem to have direct oncogenic 
effects, either by provoking damage to DNA or through 
other mechanisms not linked to immunosuppression. 
Azathioprine, for instance, induces chromosomal 
aberrations and increases skin cell sensitivity to 
photodamage[97]. 
Calcineurin inhibitors: There is evidence of direct pro-
oncogenic activity in the case of calcineurin inhibitors, 
which induce tumorigenesis and tumor growth by 
inducing cancer cell invasiveness[102], hampering DNA 
repair mechanisms[103,104] and apoptosis[103], inducing 
tumor angiogenesis via the stimulation of vascular 
endothelial growth factor (VEGF)[105], and promoting 
the transcription and functional expression of the 
TGF-β1 gene which results in tumor cell invasion and 
metastatic potential[106]. In LT recipients, it has been 
shown than exposure to elevated concentrations of 
tacrolimus (> 20 ng/mL) in the weeks immediately 
after transplantation increases long-term mortality due 
to infections, cardiovascular events and development of 
neoplasms[107-110]. 
Furthermore, both calcineurin inhibitors and steroids 
exert a diabetogenic effect, causing impaired insulin 
secretion and inducing pancreatic beta cell apoptosis[111-113]. 
As many as 5%-27% of LT recipients develop neo-onset 
diabetes mellitus, and it is associated with a negative 
impact on patient and graft survival[114-116], diabetes 
being a recognized risk factor for neoplasms, playing 
an important role especially in HCC[117]. Calcineurin 
inhibitors, especially tacrolimus, have in fact been 
shown to increase the risk of developing new-onset 
diabetes mellitus after transplantation. 
Other immunosuppressant agents: The use of 
other immunosuppressant agents, including OKT3 and 
ATG, has also been associated with an increased risk 
for the development of neoplasms after solid organ 
transplantation. Early PTLD has been shown to occur 
shortly after administration of OKT3, with an average 
of 7 mo from transplantation and/or administration to 
diagnosis of PTLD[118]. In other series, high total doses of 
OKT3, especially in individuals in whom a second course 
of therapy was administered, were associated with 
a higher frequency of lymphomas[119,120]. In contrast, 
a single-center study reporting on 1570 LT of whom 
125 patients developed de novo tumors, did not show 
any relationship between OKT3 and the development 
of de novo neoplasms; the authors note that this is 
consistent with the concept that chronic maintenance 
immunosuppression is more important than short albeit 
intense periods of immunosuppression (treated with 
OKT3)[47]. A recently published Cochrane Database 
Systematic Review evaluated the benefits and harms 
of immunosuppressive T­cell specific antibody induction 
compared with placebo, no induction, or another type 
of T-cell specific antibody induction for prevention of 
acute rejection in LT recipients, and included studies 
using T-cell specific antibodies polyclonal antibodies 
[rabbit of horse antithymocyte globulin (ATG), or 
antilymphocyte globulin (ALG)], monoclonal antibodies 
(OKT3, anti-CD2, or alemtuzumab), and IL-2 receptor 
antagonists (daclizumab, basiliximab, BT563, or 
Lo-Tact-1). The authors concluded that there were 
no statistically significant differences in terms of 
malignancy[121]. 
Mammalian target of rapamycin inhibitors: 
Mammalian target of rapamycin (mTOR) is a 
serine/threonine protein kinase downstream of the 
phophoinositide-3-kinase-related kinase family, which 
plays a fundamental role as regulator of various 
oncogenic processes including cell growth, proliferation, 
metabolism, and angiogenesis[122]. The combination of 
anti-tumoral as well as immunosuppressive properties 
render this family of drugs very attractive in the post-
transplantation setting. There is growing evidence 
that the incidence of neoplastic disease is inferior 
in patients with gradual reduction of CNI with the 
introduction of mTOR inhibitors, vs those subjects 
treated with standard-dose CNI[123]. An anti-neoplastic 
activity has been demonstrated for everolimus with 
regard to various solid tumors, and a potential role in 
HCC and cholangiocarcinoma are being increasingly 
reported[105,124-127].
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pRevenTIon
As most neoplasms are favored by immunosup-
pression, the long-term use of the lowest effective 
dose of immunosuppression to avoid rejection are 
recommended, as well as the avoidance of excessive 
sun exposure, treatment of premalignant lesions 
including warts and actinic keratoses, and avoidance 
of exposure to confirmed carcinogenic substances 
including those present in tobacco smoke. 
Screening protocols are recommended in order 
to detect malignancies in early states, increasing the 
probability of opportune treatment and improving 
prognosis[128,129]. Some recommended strategies 
include monthly skin autoexam, annual dermatological 
visit, annual Pap smear, mammography every 2 
years, annual digital rectal exam and prostate-
specific antigen determination, annual fecal occult 
blood test, colonoscopy every 10 years, annual chest 
X-ray, abdominal ultrasound, chest and abdominal 
CT scan[130-135]. A summary of preventive measures is 
provided in Table 3.
Management of neoplastic disease in LT reci­
pients: In general terms, management of malignant 
neoplasms in LT recipients is similar to that of the 
immunocompetent patient in terms of surgery, 
chemotherapy and radiotherapy, but, in contrast, one 
of the main pillars of the approach to a neoplasm in 
transplant recipients is represented by modification of 
immunosuppression, especially in tumors which are 
highly susceptible to immunosuppression, such as KS 
and PTLD.
Owing to their strong anti-angiogenic effects which 
result in inhibition of tumor growth, as well as their 
direct action on cancer cells by the inhibition of their 
dependence on the mTOR pathway for cell growth 
and survival, mTOR inhibitors are increasingly being 
used in the management of neoplasms in transplant 
recipients[105,136,137]. Since cyclosporine favors an invasive 
and aggressive tumor cell behavior, the combination 
with mTORi was hypothesized to be beneficial, 
adequately avoiding rejection while also providing 
malignancy control. This has been proven to be true, 
with significantly better survival times with mTORi plus 
cyclosporine treatment vs cyclosporine-only treatment 
in mice injected with tumor cells[138]. In fact, mTORi 
alone or mTORi plus cyclosporine impairs immunity and 
promotes allograft survival in experimental models, 
and the combination of sirolimus and everolimus with 
cyclosporine is effective in clinical transplantation, 
being approved by the Food and Drug Administration 
(FDA) for use in transplant recipients[139]. Specifically, 
everolimus is indicated for immunosuppression kidney 
heart and liver transplantation, while sirolimus has 
been approved for kidney transplantation. Malignancy 
rates post-conversion to sirolimus-based, CNI-free, 
immunosuppression regimen were significantly 
lower with respect to the CNI-based immunosuppres-
sion protocol in the RMR study and the CONVERT 
trials[140,141]. Moreover, experience in renal transplant 
recipients has demonstrated that the risk of de novo 
malignancies is significantly lower in patients treated 
with mTOR inhibitors (with or without CNIs) compared 
to patients on CNI-based regimens[142]. Thus, one of 
the recommended strategies in the management of 
post-transplant neoplasms is the conversion from CNIs 
to mTOR inhibitors or inclusion of mTOR inhibitors 
in a CNI-based immunosuppressive regimen[143-145]. 
Furthermore, in another study reporting on 10 LT 
recipients who had developed de novo neoplasms after 
LT, everolimus treatment significantly increased the 
probability of survival from 14% (in a similar historical 
cohort of patients not treated with everolimus) to 
72% at 20 mo[146]. Moreover, in a recently published 
retrospective study analyzing prognostic factors for 
patients transplanted for alcohol-related cirrhosis 
who developed non-cutaneous de novo solid organ 
neoplasms, conversion to everolimus improved 
prognosis, with one- and five-year survival rates of 
77.4% and 35.2% in patients converted to everolimus 
vs 47.2% and 19.4% in patients not treated with 
everolimus, respectively (P = 0.003)[147]. 
ReCURRenCe of non-hepaTIC 
neoplasms
With the broadening of eligibility criteria for LT, older 
patients are now being transplanted, increasing 
the probability of patients with past medical history 
of malignancy to be evaluated for LT, waitlisted, 
and transplanted. The risk of neoplastic recurrence 
upon commencement and maintenance of immuno-
suppression and its derived mortality must be weighed 
against the probability of survival without a transplant. 
Recurrence of a preexistent neoplasm can occur after 
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Table 3  Intensive screening protocols for tumor surveillance 
in liver transplant recipients (data according to[128-130])
Traditional screening Intensive screening
Annual chest X-ray Annual chest and abdominal CT
Annual abdominal ultrasound Annual abdominal ultrasound
Chest and abdominal CT Annual urologic screening with PSA 
determination
Mammography and urologic 
screening (with timing 
according to standard of care)
Annual Pap smear and mammography 
(every 1-2 yr)
Annual skin examination
Colonoscopy 1 year after LT in patients 
with adenoma on pre-LT colonoscopy, 
and repeated every 2-4 yr if more 
adenomas are found. Colonoscopy 
repetition every 10 yr in patients 
> 50-yr-old
Ears, nose and throat clinic visit in 
patients with > 20 pack year smoking
CT: Computed tomography; PSA: Prostatic specific antigen; LT: Liver 
transplant.
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LT, and according to the risk of recurrence, neoplasms 
can be classified as low recurrence risk (0%-10%) 
as in the case of cervical carcinoma, endometrial 
carcinoma, myeloproliferative disorders, and lym-
phomas; intermediate recurrence rate (11%-25%) as 
in the case of colorectal cancer, non-melanoma skin 
cancer, and thyroid carcinoma; and neoplasms with 
a high recurrence rate (> 26%) as in the case of oral 
squamous carcinoma and breast cancer[148]. There 
is consensus that the tumor type and stage of the 
disease must be carefully evaluated, and according 
to this, recommendations have been made regarding 
the waiting time between achieving clinical “cure” or 
disease control and LT[149-151]. According to American[151] 
and European[95] guidelines, proposed malignancy-
free delay periods before transplantation vary from no 
delay in cases of basal-cell skin cancers and incidental 
renal cell carcinoma, to less than 2 years in cases of 
small single focal neoplasms, low-grade bladder cancer, 
excised squamous cell carcinoma, 2 years in cases 
off testicular and thyroid neoplasms, to 2-5 years or 
more for malignant melanomas, breast cancer, invasive 
cervical cancer, and colorectal cancer. Nevertheless, 
since many patients being evaluated for LT are too 
sick to endure a long waiting period, provided that the 
neoplasm is adequately controlled and the stage of the 
neoplasm itself is not associated with a poor prognosis, 
LT may be considered before completion of the waiting 
period with informed consent of the candidate[152]. 
hCC ReCURRenCe In lT ReCIpIenTs
In spite of the 5-year 60%-80% disease-free survival 
rate after LT for HCC in cases with unresectable early 
stages of the neoplasm, recurrence does occur in 
3.5%-21% of cases, and is associated with a poor 
prognosis[153]. Tumor-related established risk factors 
for HCC recurrence after LT include high levels of 
alpha-fetoprotein[154,155], tumor grading[156,157], tumor 
stage[154,156-158], and vascular invasion[154,157,158], while im-
munosuppression-related risk factors for HCC recurrence 
are primarily the level of immunosuppression[156], 
mTOR- vs mTOR inhibitor-free immunosuppression 
regimen[154,159]. Clinical studies have shown a CNIs 
dose-dependent increase in the risk of developing HCC 
recurrence[102]. Elevated exposure to CNIs (mean trough 
concentrations of tacrolimus > 10 ng/mL or cyclosporine 
> 300 ng/mL) during the first postoperative period has 
in fact been associated with an increased risk of HCC 
recurrence[160]. Moreover, it has been observed that 
high doses of cyclosporine are associated with a lower 
recurrence-free survival in patients transplanted for 
HCC. In fact, a study on 219 patients transplanted for 
HCC undertaken in Milan revealed that elevated doses 
of cyclosporine or tacrolimus during the first 30 d after 
LT almost tripled the risk of HCC recurrence[127]. 
In contrast, mTOR inhibitors possess anti-angiogenic 
and anti-proliferative properties acting though the 
reduction of several growth factors and enhancing 
microvascular thrombosis, which correlates with lower 
metastatic potential[122,161]. The antineoplastic effect of 
mTOR inhibitors has also been shown in several clinical 
studies[162]. There is growing evidence that mTOR 
deregulation plays a significant role in hepatocellular 
carcinogenesis, and pre-clinical data indicate that 
deregulated expression of mTOR pathway effectors is 
present in 40%-50% of HCCs, and activation of the 
mTOR pathway is associated with less differentiated 
neoplasms, earlier tumor recurrence, and worse 
survival outcomes[163,164]. A recent meta-analysis 
comparing CNIs against sirolimus demonstrated a 
protective effect of the latter in terms of achieving a 
lower incidence of HCC recurrence after LT[165]. This 
protective effect was confirmed in a more recent 
meta-analysis[166], which demonstrated that sirolimus, 
compared with CNIs, was associated with lower 
HCC recurrence (OR = 0.30, 95%CI: 0.16-0.55, P < 
0.001), lower HCC recurrence-related mortality (OR 
= 0.29, 95%CI: 0.12-0.70, P = 0.005), and lower 
overall mortality (OR = 0.35, 95%CI: 0.20-0.61, P < 
0.001). In addition, a recent systematic review showed 
that patients on CNIs developed HCC recurrence 
significantly more frequently compared with patients 
on mTORi. In addition,patients on everolimus had 
significantly lower HCC recurrence rates compared with 
those on sirolimus or CNIs, although patients treated 
with mTOR inhibitors tended to have less advanced 
stages of HCC[167,168]. 
ConClUsIon
Overall, the risk of malignancy is two to four times 
higher in transplant recipients than in an age- and sex-
matched population, and cancer is expected to surpass 
cardiovascular complications as the primary cause 
of death in transplanted patients within the next 2 
decades[4,169]. De novo malignancy is a very significant 
cause of mortality, particularly for long-term survivors, 
and minimization of long-term immunosuppression 
should be aimed at reducing the incidence of de novo 
neoplasms[1,170]. Promising results in prevention of HCC 
recurrence have been reported with the use of mTOR 
inhibitors including everolimus and sirolimus[154,159,171] 
and the ongoing open-label prospective randomized 
controlled SILVER Study[172] will provide more infor-
mation on whether sirolimus-containing vs mTOR-
inhibitor-free immunosuppression is more efficacious 
in reducing HCC recurrence. The combined use of 
sorafenib, a multikinase antiangiogenic inhibitor, and 
an mTOR inhibitor has yielded positive results in 
treating patients with HCC recurrence after LT, despite 
notable associated toxity[173]. 
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